Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Brainstorm Cell Therapeutics Inc (BCLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BCLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.26% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.79M USD | Price to earnings Ratio - | 1Y Target Price 14.45 |
Price to earnings Ratio - | 1Y Target Price 14.45 | ||
Volume (30-day avg) 34706 | Beta 0.74 | 52 Weeks Range 1.05 - 11.25 | Updated Date 04/1/2025 |
52 Weeks Range 1.05 - 11.25 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.45 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.27 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -215.84% | Return on Equity (TTM) -1121.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7859317 | Price to Sales(TTM) - |
Enterprise Value 7859317 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.7 | Shares Outstanding 5703430 | Shares Floating 4430878 |
Shares Outstanding 5703430 | Shares Floating 4430878 | ||
Percent Insiders 20.8 | Percent Institutions 12.49 |
Analyst Ratings
Rating 4 | Target Price 23.45 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Brainstorm Cell Therapeutics Inc
Company Overview
History and Background
Brainstorm Cell Therapeutics Inc. was founded in 2003. It is a biotechnology company focused on developing innovative cell therapies for neurodegenerative diseases. Its lead product candidate is NurOwn (autologous MSC-NTF cells).
Core Business Areas
- Cell Therapy Development: Develops and manufactures cell therapies for neurodegenerative diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its cell therapies.
Leadership and Structure
Chaim Lebovits is the CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- NurOwn: NurOwn is an autologous cellular therapy in development for the treatment of amyotrophic lateral sclerosis (ALS). While not approved by the FDA, it has completed Phase 3 clinical trials. Competitors include Amylyx Pharmaceuticals (AMYX) with Relyvrio (approved for ALS), Mitsubishi Tanabe Pharma America with Radicava (approved for ALS), and Biogen (BIIB) with Tofersen (approved for certain genetic forms of ALS).
Market Dynamics
Industry Overview
The industry is focused on developing novel therapies for neurodegenerative diseases, with significant unmet medical needs and a growing aging population.
Positioning
Brainstorm Cell Therapeutics is positioned as a developer of innovative cell therapies for ALS, competing with larger pharmaceutical companies with established treatments.
Total Addressable Market (TAM)
The estimated global market for ALS therapeutics is expected to reach billions of dollars. Brainstorm Cell Therapeutics is positioned to capture a portion of this market if NurOwn receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy technology
- Focus on ALS, a disease with high unmet need
- Experienced management team
Weaknesses
- NurOwn is not yet FDA approved
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
Opportunities
- Potential FDA approval of NurOwn
- Expansion into other neurodegenerative diseases
- Strategic partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles
- Competition from other ALS therapies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMYX
- BIIB
- MTL.TO
Competitive Landscape
Brainstorm Cell Therapeutics faces intense competition from established pharmaceutical companies. Its advantage lies in its novel cell therapy approach, but it needs regulatory approval to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by development efforts rather than revenue generation.
Future Projections: Future growth depends on the successful development and approval of NurOwn. Analyst estimates are subject to change based on clinical trial outcomes and regulatory decisions.
Recent Initiatives: Recent initiatives include continuing clinical development of NurOwn and seeking regulatory approval.
Summary
Brainstorm Cell Therapeutics is a clinical-stage biotechnology company focused on developing NurOwn for ALS. The company's success is heavily reliant on FDA approval. Current competition in the ALS therapeutics market is strong. Financial constraints and clinical trial uncertainties present significant risks. Potential FDA approval remains the key factor for future success.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
CRIS
Curis Inc
CRIS
Curis Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and is subject to change. Market share estimates are approximate. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainstorm Cell Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2003-08-28 | President & CEO Mr. Chaim Lebovits | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.brainstorm-cell.com |
Full time employees 29 | Website https://www.brainstorm-cell.com | ||
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.